last update of this page: 29 July 2005
At my 'work' page you may have already seen that for the past ten years I have working on research into effectiveness and costs of cancer screening. I have recently gathered some of the articles on this work into a dissertation that I expect will lead to my promotion to PhD starting at 13h45 on 28 June 2000 in lecture room 7 of the medical faculty of Erasmus university. The promotion ceremony is a public meeting, therefore if you are welcome to attend.
Following is the contents table of my dissertation. You can click through to the parts that I have written specifically for this dissertation, the other parts have been published elsewhere or will hopefully be published elsewhere soon. The full text of chapter 6 is available on the web site of BMJ, and the abstracts of the other publication you can find of course in Medline.
CONTENTS | |
| 1. | Introduction |
| gathering evidence | |
| 2. |
Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials [de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst 1995;87(16):1217-23] abstract additional discussion |
| 3. |
An investigation of design and bias issues in case-control studies of cancer screening using microsimulation [Connor RJ, Boer R, Prorok PC, Weed DL. An investigation of design and bias issues in case-control studies of cancer screening using microsimulation. In press in Am J Epidemiol] additional discussion |
| 4. |
A comparison of disease specific survival of patients who died of and who had newly diagnosed prostate cancer [Boer R, de Koning HJ, Beemsterboer PM, Warmerdam PG, Schroeder FH. A comparison of disease specific survival of patients who died of and who had newly diagnosed prostate cancer. J Urol 1997;157(5):1768-71] abstract |
| 5. | Ambiguities in calculating cancer patient survival: the SEER experience for colorectal and prostate cancer [Boer R, van Ballegooijen M, Ries L, Legler J, Feuer R, Habbema J. Ambiguities in calculating cancer patient survival: the seer experience for colorectal and prostate cancer. Submitted for publication] |
| evidence and uncertainty | |
| 6. | Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study [Boer R, de Koning H, Threlfall A, Warmerdam P, Street A, Friedman E, et al. Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. BMJ 1998;317(7155):376-9] |
| 7. |
Unaided visual examination versus Pap-smears for early detection of cervical cancer [Boer R, Marjolein van Ballegooijen, Willem-Jan Meerding, Veena Singh, Ashok Sehgal, J. Dik F. Habbema. Unaided visual examination versus Pap-smears for early detection of cervical cancer. In abbreviated form in press in proceedings of Eurgin 2000 congress] additional discussion |
| balancing favourable and unfavourable effects | |
| 8. |
In search of the best upper age limit for breast cancer screening [Boer R, de Koning HJ, van Oortmarssen GJ, van der Maas PJ. In search of the best upper age limit for breast cancer screening. Eur J Cancer 1995;31A(12):2040-3] abstract additional discussion |
| 9. |
A longer breast carcinoma screening interval for women age older than 65 years? [Boer R, de Koning HJ, van der Maas PJ. A longer breast carcinoma screening interval for women age older than 65 years? Cancer 1999;86(8):1506-10] abstract |
| effectiveness and circumstances | |
| 10. | Important influences on effectiveness and costs to be considered in the evaluation of cancer screening [Boer R, de Koning H, van Ballegooijen M, van der Maas P. Important influences on effectiveness and costs to be considered in the evaluation of cancer screening. In press in: Quantitative methods of evaluation of cancer screening] |
| evidence for compelling questions | |
| 11. |
Extra incidence caused by mammographic screening [Boer R, Warmerdam P, de Koning H, van Oortmarssen G. Extra incidence caused by mammographic screening. Lancet 1994;343(8903):979] medline reference additional discussion |
| 12. |
Stage distribution at first and repeat examinations in breast cancer screening [Boer R, de Koning H, van Oortmarssen G, Warmerdam P, van der Maas P. Stage distribution at first and repeat examinations in breast cancer screening. J Med Screen 1999;6(3):132-8] abstract |
| 13. | Conclusion |
| Summary | |
| Samenvatting | |
| References | |
| Theses |
Promotion committee
Promotor:
Prof. dr. P. J. van der Maas
Other members:
Prof. dr. J. D. F. Habbema
Prof. dr. M.G.M. Hunink
Prof. dr. E.K.A. van Doorslaer
Copromotor:
Dr. ir. G. J. van Oortmarssen